Emergent BioSolutions Inc.
EBSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 9, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 10, 2025 |
| Benchmark | maintain | Buy | Nov 7, 2024 |
| Rodman & Renshaw | maintain | Buy | Sep 13, 2024 |
| Benchmark | maintain | Buy | Aug 16, 2024 |
| Benchmark | maintain | Buy | Aug 9, 2024 |
| Benchmark | maintain | Buy | Jul 3, 2024 |
| Benchmark | maintain | Buy | Jul 2, 2024 |
| Benchmark | maintain | Buy | Jun 24, 2024 |
| Benchmark | maintain | Buy | Jun 21, 2024 |
| Benchmark | maintain | Buy | Jun 20, 2024 |
| Benchmark | maintain | Buy | Apr 11, 2024 |
| Benchmark | upgrade | Hold →Buy | Mar 7, 2024 |
| Benchmark | downgrade | Buy →Hold | Aug 29, 2023 |
| Benchmark | maintain | Buy | May 31, 2023 |
| Benchmark | maintain | Buy | May 19, 2023 |
| Benchmark | upgrade | Hold →Buy | Apr 10, 2023 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-0.16| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 2, 2026 | $-0.36 | $-0.39 | $110.0M | $123.2M |
| Aug 5, 2026 | $0.60 | $-0.09 | $234.3M | $177.5M |
| Apr 30, 2026 | $0.21 | $-0.25 | $156.1M | $145.0M |
| Feb 26, 2026 | $-0.43 | $0.11 | $148.7M | $217.5M |
| Oct 29, 2025 | $1.06 | $-0.12 | $231.1M | $217.5M |
| Aug 6, 2025 | $0.16 | $-0.26 | $140.9M | $203.7M |
| May 7, 2025 | $0.71 | $0.49 | $222.2M | $219.0M |
| Mar 3, 2025 | $0.05 | $-0.35 | $189.3M | $279.0M |
News
Emergent BioSolutions remains a hold as commercial recovery is uncertain despite progress on cost savings and debt reduction. EBS lowered FY26 revenue and EBITDA guidance, citing government procurement delays and persistent pricing pressure in the U.S. naloxone market. Gross margin and profitability deteriorated sharply, with adjusted EBITDA swinging to a $4.6M loss and a net loss of $32.7M in 3Q26.
GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027. This order is under Emergent's existing indefinite-d…
Full-year revenue guidance was updated to $600 million to $645 million. Restructuring actions are expected to generate $40 million in annualized savings.
Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript
Emergent Biosolutions NYSE: EBS reported third-quarter revenue within its guidance range and updated its full-year outlook, while continuing a multiyear transformation focused on cost control, debt reduction, medical countermeasures and naloxone access.
GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation,” said Joe Papa, president and chief executive of.
GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role of interim chief financial officer effective January 1, 2027. To support a seamless transition, Rich will serve as a senior executive advisor from January 1 through March 31, 2027. “On behalf of the Board …
Emergent Biosolutions (EBS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Global biosecurity alarms are flashing after an incident at an anti-plague research facility in Siberia sparked a severe public health response. Following the fatal lab exposure of a researcher in Irkutsk region to Yersinia pestis – the bacterium causing pneumonic plague – Russian officials placed several regional hospitals under quarantine and isolated nearly 200 contacts.
Emergent Biosolutions Inc. (NYSE: EBS - Get Free Report) SVP Paul Williams sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $6.53, for a total value of $19,590.00. Following the completion of the sale, the senior vice president owned 156,098
Emergent Biosolutions Inc. (NYSE: EBS - Get Free Report) has received an average recommendation of "Hold" from the six analysts that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company.
Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a breakdown of
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company's investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. ("Emergent" or the "Company") (NYSE: EBS).
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of face value. Following completion of the…